Ephedrine proposal contains "inadequate" small business impact analysis -- SBA.
This article was originally published in The Tan Sheet
Executive Summary
EPHEDRINE PROPOSED RULE IMPACT ON SMALL BUSINESSES NEEDS FURTHER ANALYSIS via FDA outreach efforts, the Small Business Administration Office of Chief Counsel for Advocacy states in Feb. 3 comments on FDA's proposed regulation of ephedrine alkaloid-containing dietary supplements. "FDA has done an inadequate job of analyzing the impact of the regulation on small entities and in identifying and analyzing less burdensome alternatives," SBA maintains, adding the agency "should develop an outreach strategy to obtain more reliable industry data." The proposal was published in June ("The Tan Sheet" June 9, 1997, pp. 20-23).
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning